Corporation
Johnson & Johnson (Canada) Inc.
- Meetings this Parliament
- 15
- With MPs
- 5
- Since Nov 2021
- 42
- Active registrations
- 1
Most recent reported meeting: Feb 17, 2026.
Lobbying by Johnson & Johnson (Canada) Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Sep 18, 2026
Filed by Robbie Levac, General Manager
Lobbyists
- Julie Bergeron · National Director, Key Accounts Team
- Robbie Levac · General Manager
Institutions they may lobby: Canadian Institutes of Health Research (CIHR), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration, Refugees and Citizenship Canada (IRCC), Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (17)Hide details
- Discuss Canada’s talent attraction strategy as part of the expansion of the nation’s industrial and research capacity.
- Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics.
- Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
- Zero plastic waste by 2030 – Regarding potential legislative proposal regulating harmful single-use plastic items and implementing implementation of plastic waste management programs and impact on medical technologies.
- Treasury Board initiative to address international regulatory cooperation as well as their work on the Canada US, and Canada EU Regulatory Cooperation Councils
- Proposed national pharmacare. Specifically, government’s intention to introduce a national pharmacare program.
- Modernizations of the Food and Drugs Act, with respect to inspection, reporting and confidential business information.
- Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada.
- Health Canada’s multi-year Regulatory Modernization initiative to modernize the Food and Drugs Act and Regulations, specifically with respect to approval, regulation and life cycle management of therapeutic products, including Agile Regulations.
- Health Canada and the Patented Medicine Prices Review Board (PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
- Food and Drugs Act: Delays in product approvals and changes to existing products.
- COVID-19: Regarding the development of policies and programs to address the COVID-19 pandemic and support the recovery of the Canadian economy, including as it relates to tackling health equity across marginalized communities in Canada and surgical backlogs.
- Communication to officials on labelling and product monographs.
- Chemical Management Plan as related to the regulation of chemical substances, particularly as affecting ingredients used in therapeutic products.
- Canadian Drug Agency: Specifically, the creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.
- Canada’s partnerships on global health and global community impact with Johnson & Johnson relating to maternal and child health, First Nations, mental health and other areas.
- Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
Registration 964083-373927-11. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by James Brodie (37), Robbie Levac (5).
-
Reported by James Brodie · In-house (corporation)
- Jean-Sébastien Bock · Deputy Chief of Staff, Health Canada (HC)
- Eshan Naik · Director of Policy, Health Canada (HC)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Jennifer Miller · Assistant Secretary to Cabinet, Privy Council Office (PCO)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Suzy McDonald · Associate Deputy Minister, Finance Canada (FIN)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Chris Johnstone · Assistant Deputy Minister, Health Canada (HC)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
- Chris Johnstone · Assistant Deputy Minister, Health Canada (HC)
Economic DevelopmentHealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Scott Harris · Associate Deputy Minister, Immigration, Refugees and Citizenship Canada (IRCC)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Mary Ng · Minister of Export Promotion, International Trade and Economic Development, Innovation, Science and Economic Development Canada (ISED)
- Lesley Sherban · Deputy Chief of Staff & Director of Operations, Innovation, Science and Economic Development Canada (ISED)
- Meghan Pritchard · Senior Special Assistant, Executive Operations and Tour, Innovation, Science and Economic Development Canada (ISED)
- Kevin Coon · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Kirsten Hillman · Canadian Ambassador to the United States, Global Affairs Canada (GAC)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Scott Harris · Associate Deputy Minister, Immigration, Refugees and Citizenship Canada (IRCC)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Chris Johnstone · Assistant Deputy minister, Health Canada (HC)
HealthIndustry
-
Reported by James Brodie · In-house (corporation)
- Brian Clow · Deputy Chief of Staff, Prime Minister's Office (PMO)
- Patrick Travers · Senior Global Affairs Advisor, Prime Minister's Office (PMO)
- Sean Mullin · Special Advisor, Economic Affairs, Prime Minister's Office (PMO)
Industry
-
Reported by James Brodie · In-house (corporation)
- Eric Costen · Senior Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Industry
-
Reported by James Brodie · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Eric Costen · Senior Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Industry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.